At present, Keytruda is approved for two indications in melanoma. Phase III studies are ongoing evaluating Keytruda+vibostolimab coformulation in lung cancer. Merck’s stock has risen 18.6% so ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

Keytruda (pembrolizumab) is a brand-name solution for IV infusion prescribed to treat many types of cancer, including melanoma and lung cancer. As with other drugs, Keytruda can cause side effects ...

The advantages and disadvantages of CAR-T cell therapy should be carefully thought about for patients with melanoma.

Vaccines are the original immunotherapy, in the view of Ryan Sullivan, a cancer immunotherapy researcher and oncologist at ...

Iovance Biotherapeutics' strong Q3 earnings and promising drug pipeline suggest growth potential for risk-tolerant investors.

Pivotal Phase 3 trial (IOB-013/KN-D18) evaluating off-the-shelf therapeutic cancer vaccine IO102-IO103 in combination with Merck’s anti-PD-1 ...

It will assess the safety, tolerability and initial efficacy of MB097 plus MSD’s (Merck & Co.) anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in patients with cutaneous melanoma who have not ...

Melanoma symptoms to look for The musician ... high-risk melanomas who received the jab alongside the immunotherapy Keytruda were almost half (49%) as likely to die or have their cancer come ...

1 CR and 2 PRs among 11 patients with cutaneous melanoma. SD in 6 patients including 3 with duration ... Cohort 3: 120 microgram/kg Q2W MDNA11 and 400 mg Q6W KEYTRUDA; Cohort 4: 120 microgram/kg Q3W ...

In partnership with Moderna MRNA, Merck is developing a personalized mRNA therapeutic cancer vaccine (V940/mRNA-4157) in combination with Keytruda for treating adjuvant melanoma and non-small cell ...

The MELODY-1 study will investigate the safety, tolerability, and initial signals of efficacy of MB097 in advanced (metastatic) melanoma, in combination with KEYTRUDA ® (pembrolizumab), MSD's (Merck & ...